Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 8Colonic Neoplasms 3Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Peritoneal Neoplasms 1Peritoneal Metastases From Gastric Cancer 1Peritoneal Metastases From Colorectal Cancer 1Pancreatitis, Acute Necrotizing 1Pancreatic Fistula 1Pancreatic Cyst 1Neoplasm Metastasis 1Melanoma 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leiomyoma 1Krukenberg Tumor 1Infertility 1Hyperthermia 1Eye Neoplasms 1Complex Ovarian Cyst 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Laparotomy × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡